Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Assets: 2020-2024

Historic Assets for Mereo BioPharma Group (MREO) over the last 5 years, with Dec 2024 value amounting to $76.4 million.

  • Mereo BioPharma Group's Assets fell 39.60% to $53.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.6 million, marking a year-over-year decrease of 39.60%. This contributed to the annual value of $76.4 million for FY2024, which is 14.87% up from last year.
  • According to the latest figures from FY2024, Mereo BioPharma Group's Assets is $76.4 million, which was up 14.87% from $66.5 million recorded in FY2023.
  • Mereo BioPharma Group's 5-year Assets high stood at $170.4 million for FY2021, and its period low was $66.5 million during FY2023.
  • Its 3-year average for Assets is $73.4 million, with a median of $76.4 million in 2024.
  • As far as peak fluctuations go, Mereo BioPharma Group's Assets surged by 110.82% in 2021, and later slumped by 54.57% in 2022.
  • Yearly analysis of 5 years shows Mereo BioPharma Group's Assets stood at $80.8 million in 2020, then spiked by 110.82% to $170.4 million in 2021, then tumbled by 54.57% to $77.4 million in 2022, then decreased by 14.10% to $66.5 million in 2023, then climbed by 14.87% to $76.4 million in 2024.